PharmaShots Weekly Snapshots (February 19 – February 23, 2024)

Share this

PharmaShots Weekly Snapshots (February 19 – February 23, 2024)

This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:


Bavarian Nordic’s CHIKV VLP Receives EMA’s Accelerated Assessment for Chikungunya

Read More: Bavarian Nordic

The US FDA Approves Roche’s Xolair for Food Allergies

Read More: Roche                                                                               

The US FDA Approves AstraZeneca’s Tagrisso, in Combination with Chemotherapy, for Treating EGFRm Advanced NSCLC

Read More: AstraZeneca                                                                  

Iovance Receives the US FDA’s Accelerated Approval for Amtagvi (lifileucel) as a Treatment for Metastatic Melanoma (MM)

Read More: Iovance                                                                            

The US FDA’s Accepts Daiichi Sankyo and AstraZeneca’s BLA for Datopotamab Deruxtecan to Treat Non-Small Cell Lung Cancer

Read More: Daiichi Sankyo & AstraZeneca                                          

The European Commission Approves Pfizer’s Velsipity (etrasimod) for the Treatment of Severely Active Ulcerative Colitis

Read More: Pfizer                                                                            

The US FDA Accepts and Grants Priority Review to argenx’s sBLA of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Read More: argenx                                                                           

The US FDA Grants FTD to Certa Therapeutics’ FT011 for the Treatment of Systemic Sclerosis 

Read More: Certa Therapeutics                                                       

The US FDA Accepts and Grants Priority Review to Merck’s sBLA for Keytruda Plus Chemotherapy to Treat Endometrial Carcinoma

Read More: Merck                                                                            

The US FDA Accepts and Grants Priority Review to BMS’ sNDA for Krazati & Cetuximab Combination to Treat Colorectal Cancer (CRC)

Read More: BMS                                                                        

RAPT Therapeutics Reports the US FDA’s Clinical Hold on the Studies Investigating Zelnecirnon

Read More: RAPT Therapeutics                                                   

The US FDA Approves Mabwell's IND Application for 7MW3711 as a Treatment for Solid Tumors

Read More: Mabwell                                                                   

The US FDA Approves Johnson & Johnson’s sBLA of Tecvayli for Treating Relapsed/Refractory Multiple Myeloma

Read More: Johnson & Johnson                                                               

The US FDA Accepts and Grants Priority Review to Sanofi’s sBLA of Dupixent for the Treatment of COPD with Type 2 Inflammation

Read More: Sanofi                                                                            

The US FDA Grants FTD to Artiva Biotherapeutics’ AlloNK (AB-101) for the Treatment of Lupus Nephritis

Read More: Artiva Biotherapeutics                                                            

The CHMP Grants Positive Opinion to CSL Vifor and Travere Therapeutics’ Sparsentan for the Treatment of IgA Nephropathy

Read More: CSL Vifor             


Almirall and Novo Nordisk Collaborate to Develop NN-8828 for Treating Dermatological Diseases

Read More: Almirall & Novo Nordisk                                           

Immune-Onc Therapeutics and Roche Partner to Assess IO-108 for the Treatment of Advanced Hepatocellular Carcinoma

Read More: Immune-Onc Therapeutics and Roche                       

Biocytogen and Gilead have Signed a Multi-Target Antibody Collaboration Agreement to Select and Develop Therapeutic Targets for the Treatment of Multiple Disease

Read More: Biocytogen & Gilead                                                     

Mainz Biomed Collaborates with TomaLab for Enhancing the Diagnosis of Colorectal Cancer Using ColoAlert 

Read More: Mainz Biomed & TomaLab                                                     

Immunocore and BMS Collaborate for the Development of IMC-F106C in the P-III Trial for the Treatment of Melanoma

Read More: Immunocore & BMS                                                       

AbbVie and Tentarix Biotherapeutics Collaborate to Develop Biologics for Oncology and Immunology

Read More: AbbVie & Tentarix                                                     


Boehringer Ingelheim Collaborates with Sleip AI to Utilize AI-technology for Detecting Lameness in Horse

Read More: Boehringer Ingelheim & Sleip AI                              

Ono Pharmaceutical and InveniAI Sign a Research Collaboration Agreement for the Identification of Novel Therapeutic Targets Using AI and ML

Read More: Ono Pharmaceutical & InveniAI             


Innovent Highlights the P-III (RESTORE-1) Trial Results of IBI311 to Treat Thyroid Eye Disease (TED) 

Read More: Innovent                                                                    

ViiV Healthcare (GSK & Pfizer’s Global Specialist HIV Company) Highlights P-III (LATITUDE) Trial Results of Cabenuva (cabotegravir + rilpivirine) for HIV 

Read More: ViiV Healthcare                                                   

Aleta Biotherapeutics Doses First Patient with ALETA-001 in P-I/II Trial for the Treatment of R/R B-Cell Malignancies

Read More: Aleta Biotherapeutics                                                      

CymaBay Publishes P-III Results for Seladelpar as a Treatment of Primary Biliary Cholangitis in the New England Journal of Medicine 

Read More: CymaBay                                                                     

SynAct Pharma Highlights Further Analysis from the P-IIb (EXPAND) Study Supporting the Development of Resomelagonin for Rheumatoid Arthritis

Read More: SynAct Pharma                                                                        


Mabwell Publishes the P-III Study Results of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology

Read More: Mabwell                                                                               

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions